ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually present the Company’s anti-infective portfolio and...
Source: forextv.com